Wednesday, June 10, 2015 5:00 p.m. - 6:00 p.m. - LAUNCH 6:00 p.m. - 7:00 p.m. - RECEPTION
Johns Hopkins University School of Medicine
Sheikh Zayed Tower
ZAYED 2119A
1800 Orleans Street
Baltimore, MD 21287
SANOFI PARTICIPANTS:
Elias Zerhouni, President, Sanofi GlobalR&D Sridar Natasan, VP, Sanofi NA Strategic Initiatives & Scientific Relations Karen Chandross, Sr Director, NA Strategic Initiatives & Scientific Relations Kathy Klinger, Scientific Fellow Presidential, Genzyme Genomics Center Bruce Roberts, VP, Genzyme Immunology Mike Panzara, VP, Genzyme MS/Neurology Lana Skirboll, VP, Academic & Scientific Affairs
Sanofi iAwards Program Initiative
Wednesday, June 10, 2015 Zayed 2119A 5:00 p.m. Launch / 6:00 p.m. Reception
Launch Announcement
Sanofi is a leading global healthcare company engaged in the research, development, manufacturing and marketing of innovative therapeutic solutions aimed at improving people’s lives. Sanofi Global R&D is currently developing innovative vaccines and medicines to treat diabetes, cardiovascular disease, rare disease, immune mediated disease, cancer, infectious disease, neurodegenerative disease, and animal health. To continue to bring new and effective medicines to patients, Sanofi is committed to accelerating the translation of innovative academic ideas into breakthrough therapeutic solutions with measurable impact on health outcomes. Towards this goal, Sanofi and John Hopkins School of Medicine are proud to announce a new initiative, the Sanofi Innovation Awards (Sanofi iAwards) program.
The Sanofi iAwards program brings together seven world-class academic institutions and is intended to:
The expected outcome of the Sanofi iAwards initiative is additional sponsored research funding and joint collaboration to support further advancement of the science behind these innovative ideas.
The Sanofi iAwards is Sanofi’s latest initiative towards building a stronger relationship with academia around specific projects and is designed to leverage the complementary expertise of academia and industry by bringing our individual strengths together towards translating science and technology innovations into new potential therapies for patients.